Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm. Other participating investors include Series B Co-leads GL Ventures (venture capital arm of Hillhouse Group) and Sequoia Capital, and Series A lead VC Co-win Ventures.

At Amador we provide global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.

Amador Bioscience Announces The Completion Of $60 Million Series B+ Round Financing

Description

Company Information

Funding Insights

Amador Bioscience Announces The Completion Of $60 Million Series B+ Round Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information